The DOI matches its Crossref record; 258 of the 258 references it cites were found in a registry or an index.
Treating inflammation by blocking interleukin-1 in humans
Open accessAbstract
IL-1 is a master cytokine of local and systemic inflammation. With the availability of specific IL-1 targeting therapies, a broadening list of diseases has revealed the pathologic role of IL-1-mediated inflammation. Although IL-1, either IL-1α or IL-1β, was administered to patients in order to improve bone marrow function or increase host immune responses to cancer, these patients experienced unacceptable toxicity with fever, anorexia, myalgias, arthralgias, fatigue, gastrointestinal upset and sleep disturbances; frank hypotension occurred. Thus it was not unexpected that specific pharmacological blockade of IL-1 activity in inflammatory diseases would be beneficial. Monotherapy blocking IL-1 activity in a broad spectrum of inflammatory syndromes results in a rapid and sustained reduction in disease severity. In common conditions such as heart failure and gout arthritis, IL-1 blockade can be effective therapy. Three IL-1blockers have been approved: the IL-1 receptor antagonist, anakinra, blocks the IL-1 receptor and therefore reduces the activity of IL-1α and IL-1β. A soluble decoy receptor, rilonacept, and a neutralizing monoclonal anti-interleukin-1β antibody, canakinumab, are also approved. A monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1α are in clinical trials. By specifically blocking IL-1, we have learned a great deal about the role of this cytokine in inflammation but equally important, reducing IL-1 activity has lifted the burden of disease for many patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–258 of 258
IL-1RA Agonist (Anakinra) in the Treatment of Multifocal Castleman Disease
Galeotti, C., Tran, T.-A., Franchi‐Abella, S., Fabrè, M., Pariente, D., & Koné‐Paut, I. (2008) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e31818ab31f · Cited by 60
An Overview of Interleukin-1 Receptor Antagonist, Anakinra, in the Treatment of Cutaneous Diseases
Pazyar, N., Feily, A., & Yaghoobi, R. (2012) · Current Clinical Pharmacology · doi:10.2174/157488412803305821 · Cited by 60
How interleukin‐1β induces gouty arthritis
Dinarello, C. A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27663 · Cited by 59
Self-citationMonocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia
Rosengren, S., Mueller, J. L., Anderson, J. P., Niehaus, B. L., Misaghi, A., Anderson, S., Boyle, D. L., & Hoffman, H. M. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.12.649 · Cited by 58
Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury
Rusai, K., Huang, H., Sayed, N., et al. (2008) · Transplant International · doi:10.1111/j.1432-2277.2008.00651.x · Cited by 58
Settas, L., Tsimirikas, G., Vosvotekas, G., Triantafyllidou, E., & Nicolaides, P. (2007) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31812e00a1 · Cited by 57
Schnitzler syndrome: an under-diagnosed clinical entity
Jain, T., Offord, C. P., Kyle, R. A., & Dingli, D. (2013) · Haematologica · doi:10.3324/haematol.2013.084830 · Cited by 57
Jaeger, T., ANDRES, C., Grosber, M., Zirbs, M., Hein, R., Ring, J., & Traidl‐Hoffmann, C. (2013) · European Journal of Dermatology · doi:10.1684/ejd.2013.2018 · Cited by 55
Mitroulis, I., Skendros, P., Oikonomou, A., Tzioufas, A. G., & Ritis, K. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146878 · Cited by 55
Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA)
Ohlsson, V., Baildam, E. M., Foster, H., Jandial, S., Pain, C. E., Strike, H., & Ramanan, A. V. (2007) · Lara D. Veeken · doi:10.1093/rheumatology/ken030 · Cited by 55
Cantarini, L., Lucherini, O. M., Cimaz, R., & Galeazzi, M. (2010) · PubMed · Cited by 55
Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: an overview
Aronson, I. K., & Worobec, S. M. (2010) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2010.01339.x · Cited by 54
Ogilvie, A. C., Hack, C. E., Wagstaff, J., van Mierlo, G. J., Erenberg, A. J., Thomsen, L. L., Hoekman, K., & Rankin, E. M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.1.389 · Cited by 54
Pillinger, M. H. (2006) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70352-3 · Cited by 54
Furlan, A., Botsios, C., Ruffatti, A., TODESCO, S., & Punzi, L. (2008) · Joint Bone Spine · doi:10.1016/j.jbspin.2007.07.010 · Cited by 53
Furuta, T., Teranishi, M., Uchida, Y., Nishio, N., Kato, K., Otake, H., Yoshida, T., Tagaya, M., Suzuki, H., Sugiura, M., et al. (2011) · International Journal of Immunogenetics · doi:10.1111/j.1744-313x.2011.01004.x · Cited by 53
Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
McDermott, M., & Gillespie, J. (2010) · Journal of Inflammation Research · doi:10.2147/jir.s8109 · Cited by 51
Bodar, E. J., Simon, A., de Visser, M., & van der Meer, J. W. M. (2009) · PubMed · Cited by 51
Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome
de Koning, H. D., Schalkwijk, J., van der Meer, J. W. M., & Simon, A. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.05.023 · Cited by 50
Current and future treatments for Behçet’s uveitis: road to remission
Mesquida, M., Molins, B., Llorenç, V., Hernández, M. V., Espinosa, G., Dick, A., & Adán, A. (2014) · International ophtalmology · doi:10.1007/s10792-013-9788-5 · Cited by 49
Hyper-IgD syndrome or mevalonate kinase deficiency
Stoffels, M., & Simon, A. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328349c3b1 · Cited by 48
Turkstra, E., Ng, S., & Scuffham, P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.608655 · Cited by 48
Lucherini, O. M., Obici, L. P., Ferracin, M., Fulci, V., McDermott, M., Merlini, G., Muscari, I., Magnotti, F., Dickie, L. J., Galeazzi, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073443 · Cited by 47
Pontifex, E. K., Gerlag, D. M., Gogarty, M., Vinkenoog, M., Gibbs, A., Burgman, I., Fearon, U., Bresnihan, B., Tak, P. P., Gibney, R. G., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3228 · Cited by 47
Raffeiner, B., Botsios, C., Dinarello, C. A., Ometto, F., Punzi, L., & Ramonda, R. (2010) · Joint Bone Spine · doi:10.1016/j.jbspin.2010.09.014 · Cited by 45
Self-citationAnakinra for the treatment of adult-onset Still’s disease
Castañeda, S., Atienza‐Mateo, B., Martín-Varillas, J. L., López-Matencio, J. M. S., & González-Gay, M. Á. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1536548 · Cited by 45
Church, L. D., Savic, S., & McDermott, M. (2008) · Biologics · doi:10.2147/btt.s3167 · Cited by 43
Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis
Moltó, A., Ea, H., Richette, P., Bardin, T., & Lioté, F. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.01.010 · Cited by 43
Imagawa, T., Nishikomori, R., Takada, H., Takeshita, S., Patel, N., Kim, D. S., Lheritier, K., Heike, T., Hara, T., & Yokota, S. (2013) · PubMed · Cited by 42
Loh, N. K., Lucas, M., Fernández, S., & Prentice, D. A. (2012) · Internal Medicine Journal · doi:10.1111/imj.12002 · Cited by 42
Swart, J. F., Barug, D., Möhlmann, M., & Wulffraat, N. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.532785 · Cited by 42
A historical view from thirty eventful years of immunotherapy in autoimmune diabetes
Bach, J.-F., & Chatenoud, L. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.07.009 · Cited by 41
Kavanaugh, A. (2006) · Advances in Therapy · doi:10.1007/bf02850127 · Cited by 40
Aubert, P. M., Suárez‐Fariñas, M., Mitsui, H., Johnson-Huang, L. M., Harden, J. L., Pierson, K. C., Dolan, J. G., Novitskaya, I., Coats, I., Estes, J. D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049408 · Cited by 40
Canakinumab in Schnitzler Syndrome
Vanderschueren, S., & Knockaert, D. C. (2012) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2012.06.003 · Cited by 40
Lipsker, D. M., Perrigouard, C., Foubert, A., & Cribier, B. J. (2010) · Dermatology · doi:10.1159/000280436 · Cited by 39
IL-1 Inhibition With Anakinra in a Patient With Refractory Gout
Singh, D., & Huston, K. K. (2009) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e3181be2423 · Cited by 39
Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra
Aubert, O., Aouba, A., Deshayes, S., et al. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.07.005 · Cited by 36
Scott, I. C., Hajela, V., Hawkins, P. N., & Lachmann, H. J. (2011) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2011.07.003 · Cited by 34
Sustained response to anakinra in ankylosing spondylitis
Bennett, A. N., Tan, A. L., Coates, L. C., Emery, P., Marzo‐Ortega, H., & McGonagle, D. (2007) · Rheumatology · doi:10.1093/rheumatology/kem302 · Cited by 33
Hennig, S., Bayegan, K., Uffmann, M., Thalhammer, F., & Winkler, S. (2010) · Rheumatology International · doi:10.1007/s00296-010-1429-y · Cited by 33
Anakinra prevents symptoms of familial cold autoinflammatory syndrome and Raynaud's disease.
Metyas, S., & Hoffman, H. M. (2006) · PubMed · Cited by 32
Punzi, L., Gava, A., Galozzi, P., & Sfriso, P. (2011) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2011.10.017 · Cited by 31
Clinical Benefits of Intra-Articular Anakinra for Arthrofibrosis
Brown, C. A., Toth, A. P., & Magnussen, B. (2010) · Orthopedics · doi:10.3928/01477447-20101021-09 · Cited by 31
Balow, J. E., Ryan, J., Chae, J. J., Booty, M. G., Bulua, A. C., Stone, D. L., Sun, H., Greene, J., Barham, B. K., Goldbach‐Mansky, R. T., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202082 · Cited by 31
Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein
Courcoul, A., Vignot, E., & Chapurlat, R. D. (2013) · Joint Bone Spine · doi:10.1016/j.jbspin.2013.06.013 · Cited by 28
Botsios, C., Sfriso, P., Furlan, A., Ostuni, P., Biscaro, M., Fiocco, U., TODESCO, S., & Punzi, L. (2011) · Reumatismo · doi:10.4081/reumatismo.2007.32 · Cited by 26
Chauffier, K., London, J., Beaudouin, C., & Fautrel, B. (2009) · La Presse Médicale · doi:10.1016/j.lpm.2009.01.012 · Cited by 24
First observation of the efficacy of IL-1ra to treat tophaceous gout of the lumbar spine
Funck‐Brentano, T., Salliot, C., Leboime, A., Zafrani, L., Servais, A., Larousserie, F., & Dougados, M. (2010) · Rheumatology · doi:10.1093/rheumatology/keq358 · Cited by 23
Diamantopoulos, A. P., Brodin, C., Hetland, H., & Haugeberg, G. (2012) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31826149a2 · Cited by 22
Anakinra for the inflammatory complications of chronic granulomatous disease.
van de Veerdonk, F. L., Netea, M. G., Dinarello, C. A., & van der Meer, J. W. M. (2011) · PubMed · Cited by 21
Self-citationVolz, T., Wölbing, F., Fischer, J., et al. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1307 · Cited by 21
Klein, A., & Horneff, G. (2010) · Klinische Pädiatrie · doi:10.1055/s-0029-1239527 · Cited by 20
Genant, H. K., Bresnihan, B., Ng, E., Robbins, S., Newmark, R., & McCabe, D. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2001.1196 · Cited by 19
Anakinra for a refractory case of intermittent hydrarthrosis with a TRAPS-related gene mutation
Andrés, M., & Pascual, E. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202087 · Cited by 18
Muckle-Wells syndrome: a treatable cause of congenital sensorineural hearing loss.
Stew, B. T., Fishpool, S. J. C., Owens, D., & Quine, S. M. (2013) · PubMed · Cited by 13
Nephrotic Syndrome and AA Amyloidosis Revealing Adult-Onset Cryopyrin-Associated Periodic Syndrome
Enríquez, R., Sirvent, A. E., Padilla, S., Noguera-Pons, R., Andrada, E., Ardoy, F., Millán, I., & Amorós, F. (2013) · Renal Failure · doi:10.3109/0886022x.2013.790300 · Cited by 11
Mueller, S. M., Itin, P. H., & Haeusermann, P. (2011) · Dermatology · doi:10.1159/000331580 · Cited by 8
Cited by
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Cytokines in Inflammatory Disease
Kany, S., Vollrath, J. T., & Relja, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236008 · Cited by 1,971
Overview of the IL ‐1 family in innate inflammation and acquired immunity
Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12621 · Cited by 1,866
Self-citationChamorro, Á., Dirnagl, U., Urra, X., & Planas, A. M. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00114-9 · Cited by 1,198
Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders
Jiang, H., He, H., Chen, Y., Huang, W., Cheng, J., Ye, J., Wang, A., Tao, J., Wang, C., Liu, Q., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171419 · Cited by 748
Metadata
- Authors
- Dinarello, C. A., & van der Meer, J. W. M.
- Venue
- Seminars in Immunology
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 25
- Issue
- 6
- Pages
- 469-484
- ISSN
- 1044-5323 (ISSN-L)
- OpenAlex
- W2124335748
- Cited by
- 549
- References
- 258
- FWCI
- 17.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.